Could a vaccine finally stop the 'Snail Fever'?
NCT ID NCT05762393
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a new vaccine called SchistoShield® in 120 healthy adults in Burkina Faso and Madagascar. The goal was to see if it is safe and triggers an immune response against schistosomiasis, a parasitic disease spread by snails. Participants received three doses of the vaccine or a placebo, with different strengths being tested.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
SchistoShield® vaccine (rSm-p80 antigen with GLA-SE adjuvant)
What this could lead to
If successful, this could lead to the first vaccine to prevent schistosomiasis, a parasitic disease affecting millions.
What could go wrong
This is an early Phase 1b trial focused on safety and immune response, not yet on preventing infection. The vaccine may not provide sufficient protection or could have side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SCHISTOSOMIASIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Groupe de Recherche Action en Santé (GRAS)
Ouagadougou, Burkina Faso
-
Madagascar Institute for Vaccine Research (University of Antananarivo)
Antananarivo, Madagascar